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Dear Dr Whetstine, 
We would like to submit the revised version of our manuscript entitled “Novel 
multiple sclerosis susceptibility loci implicated in epigenetic regulation”. 
Thank you very much for the detailed and thoughtful reviews. We have 
answered and fulfilled all suggestions by the reviewers, and hope that the 
manuscript is now acceptable for publication in Science Advances. 
 
With best regards, 
 
 
 
 
Bernhard Hemmer and Bertram Müller-Myhsok 
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Response to reviewers 
 
We thank the reviewers for their positive and helpful comments. We have incorporated all 
suggested changes and address the reviewers’ comments in detail below.  
 
Reviewer 1 Comments to Author:  
1. As regards statistical power, your sentence ("We expected to have sufficient power to 
detect novel associations with moderate effect sizes in our data set of roughly 4000 cases 
showing low population stratification") should be better framed with a more detailed range 
of effect size identified with used sample size. 
 
We agree with the reviewer that this statement needed clarification. We have added power 
analyses for two different effect sizes covering the range relevant for this manuscript (page 7, 
last sentence of the introduction). 
 
2. I would smooth in the discussion the conclusions of the predominant role of epigenetic 
regulatory mechanisms in MS, or add additional functional work to reinforce this strong 
statement. Apart from SHMT1, the functional link of identified variants with epigenetic 
mechanisms of the other 4 variants should be demonstrated and it is only based on the 
function of the genes pointed by the variants.  
 
We agree with the reviewer that we cannot directly prove a link between MS susceptibility and 
the epigenetic mechanisms, which the genes we describe in our study are connected to. 
Nonetheless, we believe that it is worth describing the connections of the novel genes to 
epigenetic mechanisms, especially in the case of SHMT1. In our opinion it is beyond the 
scope of this study to demonstrate which of these functions are responsible for MS 
susceptibility. The mechanistic link between these genes and MS should be addressed in 
future work. We have therefore smoothed out the discussion, shortened the relevant 
paragraph and stated more clearly that it constitutes a hypothetical discussion (page 15, 
second paragraph (While a clearer picture has…), until the end of the discussion). 
 
 
Reviewer 2 Comments to Author:  
1a. The authors suggestion that their observed association with rs2812197 is novel is not 
sustainable. These same authors have recently published genomewide significant 
association with rs806349 and thereby have already established this association (authors 
ref 28). In this new study the authors show convincingly that association at rs806349 is 
secondary to rs2812197 but this does not make the association with rs2812197 a novel 
finding. The authors should re-word their paper to indicate that they have found 15 
genomewide significant associations 11 of which are known and 4 of which are novel OR 
should indicate that in preparation of this work one of the 5 novel findings has been 
independently confirmed (by them!). 
 
We apologize that our wording regarding rs2812197 was misleading. We were trying to point 
out that a variant in DLEU1 reached genome-wide significance for the first time in a GWAS. 
However, we understand the reviewer’s concern that this does not qualify as a novel 
association and therefore have changed the wording throughout the text.  
We now state within the results section: “Variants at fifteen loci outside the MHC region 
showed genome-wide significance. Ten of these loci have already been established in 
previous large MS GWAS. One more locus, DLEU1, was only recently confirmed to be 
associated with MS in a candidate SNP study. The remaining four signals are thus novel 
candidates for MS susceptibility loci.” (page 9, second paragraph).  
Accordingly, we now write in the discussion: “Four of the 15 non-MHC loci have not been 
found to be associated with MS in previous studies. One more locus, DLEU1, did not reach 
genome-wide significance in previous GWAS but has recently been confirmed as MS-
associated in a candidate SNP study.” (page 13, last paragraph). 
We conclude from the reviewer’s comment that it is still worth examining DLEU1 in detail, as 
we can show that published variants for the locus are most likely not the causal ones. We 
have therefore moved our results regarding the DLEU1 locus to the end of the results section 
(page 12, last paragraph). Furthermore, we have added a detailed comparison to previous 
Blinded AuthorComments to Editor and Reviewers
findings in the new table 5, which summarizes our analyses regarding DLEU1. We have 
removed this comparison from the discussion to avoid repetitions. 
 
1b. Furthermore in the WTCCC2 MS GWAS (the authors ref 6) a total of 102 associated 
SNPs were identified in the screening phase one of which was rs806321 from the DLEU1 
region. This SNP is in strong LD with rs2812197, the authors should thus also mention ref 
6 as previously having implicated this region/gene.  
 
We have now also incorporated this variant in the results (page 12, last paragraph), table 5, 
and fig. S6. 
 
1c. In the discussion the authors say "Five of the primary signals reaching genome-wide 
significance in the pooled analysis of DE1 and DE2 have not been established in previous 
GWAS as MS susceptibility loci so far or have been attributed to other variants, as is the 
case for DLEU1" Given that rs806321 and rs2812197 have an R squared of 0.65 it is not 
reasonable for the authors to suggest that previous studies implicating DLEU1 have 
identified independent variants. This suggestion should be removed.  
 
We have removed this sentence from the manuscript. We now write: “Four of the 15 non-
MHC loci have not been found to be associated with MS in previous studies. One more locus, 
DLEU1, did not reach genome-wide significance in previous GWAS but has recently been 
confirmed as MS-associated in a candidate SNP study.” (page 13, last paragraph). 
 
1d. Again I am not sure I follow what is meant by the statement "The DLEU1 locus contained 
a second signal, rs9591325," do the authors mean that after conditional analysis on the 
lead SNP this SNP shows association? Or do they mean that this is another SNP in the 
region which shows association but is only modestly correlated with the lead SNP? This 
needs to be clarified. The authors note that association with rs9591325 is reduced after 
conditioning on rs2812197, but should also describe the reverse, is rs2812197 still 
associated after rs9591325 and by how much? The R-squared between these SNPs is 
modest. Genetically it would seem that rs2812197 is a stronger candidate than 
rs9591325 but the authors observe that rs9591325 lies in a more functionally active 
region. However I think their statement that rs9591325 is therefore the most likely to be 
causal is not fully justified. It would seem reasonable to explain that their study lacks the 
power to fine map this region, which might of course contain more than one associated 
variant, and that rs9591325 has more functional data to support its relevance, but to claim 
it is the most likely causal variant is unjustified. 
 
We apologize that the description of rs9591325 was confusing. We changed the sentence as 
follows: “The DLEU1 locus contains evidence for a second signal, rs9591325, [...]” (page 13, 
second paragraph). As the reviewer states, we did not have enough power in our study to 
prove that both signals are independent. We have added more detailed analyses to support 
our hypothesis that “The two signals were partially independent of each other” (page 13, 
second paragraph). As the reviewer suggested, we have conducted a detailed conditional 
analysis in both directions that is described in table 5. Finally, we now point out that we 
cannot fully separate between both signals in our study: “While rs2812197 shows the overall 
strongest association at DLEU1, the functional data indicate that rs9591325 might be either 
the actual or a second causal variant. Additional studies with larger sample sizes are required 
to fully answer this question.” (page 13, end of results section).  
 
2. Supplementary table S5 is very detailed but contains a lot of primary information. I think 
that at least the main results from this table should be included in the main text. The 
results for the known associated variants in the Sardinian population should be included. 
Details about the number of SNPs in each region and how many were genotyped can 
stay in the supplementary file. The results section "Additional novel candidate loci 
associated with MS" is largely a description of details in table S5, once this is in the main 
text this section can be radically reduced/rationalised. 
 
In order to address the reviewer’s suggestion, we have reduced the information included in 
fig. 1 and instead generated a new table (table 3) that contains part of the information from 
former fig. 1 as well as the key data from former table S5. We have tried to balance the 
information included in the new table 3 to make it as informative as possible to the reader yet 
also make sure that it still fits onto an A4 page. The remaining information of former table S5 
can now be found under the new name table S4. Furthermore, we have shortened the details 
described in the results section, as the reviewer suggested. 
 
3. Given that the authors found 58 variants with lower and 35 with higher OR, it is clear that 
they did in fact find more OR values were reduced than were increased. This difference 
may not have reached statistical difference from chance but 58 is certainly larger than 35. 
In which case I don't follow the statement "Thus we observed neither an increased 
number of lower nor of higher ORs than expected by chance (binomial test p-values 0.14 
(CI 0.47-1.00) and 1.00 (CI 0.26-1.00), respectively)." Regression to the mean would 
predict that more OR should be reduced than would be increased and I think it would be 
more helpful to the reader to point out that the observed changes are in line with that 
expected after regression to the mean. 
 
We agree with the reviewer that our wording was convoluted here. Accordingly, we have 
revised the sentence: “58 of the variants had lower and 35 higher ORs in our data than in the 
published data set. It was expected to observe more signals with lower ORs than previously 
reported due to regression towards the mean.” (page 10, end of first paragraph). 
 
4. In describing the rs4925166 associated region the authors state that "The most strongly 
associated genotyped SNP, rs12946752, reached a p-value of 3.57×10-9." I don't 
understand this statement. Firstly rs4925166 is more strongly associated and secondly 
rs12946752 is a perfect proxy for rs4925166. This sentence should be clarified or 
removed, does this concern which SNPs were genotyped and which imputed? If so it is 
not clear which is which. 
 
In this sentence of our initial manuscript, we described the strongest association of a 
genotyped (and not imputed) SNP. We have followed the reviewer’s suggestion to condense 
the detailed description of results. Comparisons of results regarding imputed vs. genotyped 
variants have thus been removed from the results section. Instead, the number of genome-
wide significant imputed and genotyped SNPs is listed in table S4. 
 
5. Have the authors undertaken systematic conditional analysis on the lead SNP in each of 
their genomewide significant regions? Do any of these contain genomewide significant 
secondary signals? If this has not been done it should be done and should be reported. 
 
We have done this analysis and added its results to the manuscript: “When conditioning for 
the lead variants at these four newly identified MS-associated loci, no evidence for secondary 
signals was found. Thus, the lead variants also constitute the most likely causal variants.” 
(page 12, second paragraph). 
 
6. The authors make no more than passing mention of the MHC. They should include a 
more detailed analysis of this region. Is the most associated SNP tagging 15:01? Have 
the authors imputed the classical HLA genotypes and tested these for association. Do 
they see the same HLA associations reported by the IMSGC (of which they seem to be a 
part). The authors should provide an MHC results section. 
 
We had not focused on a description of the MHC region simply because our findings were in 
line with studies by the IMSGC. However, as a result of the reviewer’s suggestion, we have 
conducted a thorough analysis of associations with HLA alleles. We have incorporated this 
analysis in a new results section titled “Associations within the MHC region” (beginning on 
page 8). We describe imputation of classical HLA alleles and their analysis in the text and the 
new table 2. The most strongly associated SNP is indeed tagging DRB1*15:01, as outlined in 
the revised manuscript. 
 
7. Have the authors looked for any effect on age at onset or evidence of interaction between 
loci, especially between MHC and non-MHC loci. It would seem logical to describe the 
results of such analysis. 
 
We have examined the age at onset but no signal was genome-wide significant. In addition, 
the top signal confirmed previous findings by the IMSGC. We have included this analysis in 
the first paragraph on page 9 as well as in the new fig. S3. 
 
We analyzed potential interactions between loci, but no significant interactions were found. 
We summarize this result with the sentence: “We could not detect any significant interactions 
among the 15 top non-MHC variants or between them and SNP rs3104373 within the MHC 
region.” (page 9, end of second paragraph). 
 
 
General remarks regarding the revised manuscript: 
In addition to incorporating the modifications suggested by the reviewers, we have slightly 
shortened the text throughout the manuscript to improve readability.  
Some questions by the reviewers required additional calculations in the statistical software R. 
In order to make results consistent and comparable throughout the manuscript, we have 
recalculated all associations of lead variants in R. Due to differences regarding how numbers 
are rounded by the two applications, some p-values have changed very slightly compared to 
previous calculations using PLINK. MAFs have now been consistently calculated on controls. 
Previous tables S3 and S4 have been combined into one table S3. Accordingly, the 
designations of the additional supplementary tables have been adapted. 
We came to the conclusion that the previous fig. S8F is informative enough for the reader to 
justify moving it to the main figures as fig. 3C. If you do not approve of this change, we could 
move this figure back to the supplementary material. 
 
We believe that the manuscript has significantly improved with the help of the reviewers and 
hope that it is now acceptable for publication in Science Advances. 
  
 
Science Advances                                               Manuscript Template                                                                                           Page 1 of 34 
 
H1 FRONT MATTER 
H2: Title  
Long title: 
Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation  
Short title: 
Novel MS susceptibility loci 
Teaser: 
Genome-wide study in Germans confirms known and identifies four novel multiple sclerosis 
gene loci. 
 
H2:Authors 
T.F.M. Andlauer1,2†, D. Buck3†, G. Antony4, A. Bayas5, L. Bechmann6,7, A. Berthele3, A. Chan8, C. 
Gasperi3, R. Gold8, C. Graetz9, J. Haas10, M. Hecker11, C. Infante-Duarte12, M. Knop1, T. Kümpfel13, V. 
Limmroth14, R.A. Linker15, V. Loleit3, F. Luessi9, S.G. Meuth16, M. Mühlau2,3, S. Nischwitz1, F. Paul12, 
M. Pütz17, T. Ruck16, A. Salmen8, M. Stangel18, J.P. Stellmann19, K.H. Stürner19, B. Tackenberg17, F. Then 
Bergh20, H. Tumani21,22, C. Warnke23, F. Weber1,24, H. Wiendl16, B. Wildemann10, U.K. Zettl11, U. 
Ziemann25, F. Zipp9, J. Arloth1,26, P. Weber1, M. Radivojkov-Blagojevic27, M.O. Scheinhardt28, T. 
Dankowski28, T. Bettecken1, P. Lichtner27,29, D. Czamara1, T. Carrillo-Roa1, E.B. Binder1,30, K. Berger31, 
L. Bertram32,33, A. Franke34, C. Gieger35,36, S. Herms37,38, G. Homuth39, M. Ising1, K.-H. Jöckel40, T. 
Kacprowski39, S. Kloiber1, M. Laudes41, W. Lieb42, C.M. Lill32,9, S. Lucae1, T. Meitinger27,29, S. 
Moebus40, M. Müller-Nurasyid43,44,45, M.M. Nöthen37, A. Petersmann46, R. Rawal35,36, U. Schminke47, K. 
Strauch43,48, H. Völzke49, M. Waldenberger35,36, J. Wellmann31, E. Porcu50, A. Mulas50,51, M. Pitzalis50, C. 
Sidore50, I. Zara52, F. Cucca50,51, M. Zoledziewska50,51, A. Ziegler28,53,54, B. Hemmer2,3*, B. Müller-
Myhsok1,2,55* 
H2:Affiliations  
1Max Planck Institute of Psychiatry, Munich, Germany. 
Manuscript Click here to download Manuscript AndlauerText.docx 
Science Advances                                               Manuscript Template                                                                                           Page 2 of 34 
 
2Munich Cluster for Systems Neurology (SyNergy), Germany. 
3Department of Neurology, Klinikum Rechts der Isar, Technische Universität München, 
Germany. 
4Central Information Office KKNMS, Philipps University Marburg, Germany. 
5Department of Neurology, Klinikum Augsburg, Germany. 
6Department of Neurology, University of Leipzig, Germany. 
7Institute of Medical Microbiology, Otto-von-Guericke University, Magdeburg, Germany. 
8Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, Germany. 
9Department of Neurology, Focus Program Translational Neurosciences (FTN) and Research 
Center for Immunotherapy (FZI), Rhine-Main Neuroscience Network (rmn2), University 
Medical Center of the Johannes Gutenberg University Mainz, Germany. 
10Department of Neurology, University Hospital Heidelberg, Germany. 
11Department of Neurology, University of Rostock, Germany. 
12NeuroCure Clinical Research Center, Department of Neurology, and Experimental and Clinical 
Research Center, Max Delbrück Center for Molecular Medicine, and Charité University 
Medicine Berlin, Berlin, Germany. 
13Institute of Clinical Neuroimmunology, Ludwigs-Maximilians-Universität, Munich, Germany. 
14Department of Neurology, Hospital Köln-Merheim, Germany. 
15Department of Neurology, University Hospital Erlangen, Germany. 
16Department of Neurology, Klinik für Allgemeine Neurologie, University of Münster, Germany. 
Science Advances                                               Manuscript Template                                                                                           Page 3 of 34 
 
17Clinical Neuroimmunology Group, Department of Neurology, Philipps-University of Marburg, 
Germany. 
18Department of Neurology, Hannover Medical School, Germany. 
19Institute of Neuroimmunology and MS and Department of Neurology, University Medical 
Centre Hamburg-Eppendorf, Germany. 
20Department of Neurology and Translational Center for Regenerative Medicine, University of 
Leipzig, Germany. 
21Department of Neurology, University of Ulm, Germany. 
22Neurological Clinic Dietenbronn, Schwendi, Germany. 
23Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. 
24Neurological Clinic, Medical Park, Bad Camberg, Germany. 
25Department of Neurology & Stroke and Hertie-Institute for Clinical Brain Research, Eberhard-
Karls-Universität Tübingen, Germany. 
26Institute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany. 
27Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany. 
28Institut für Medizinische Biometrie und Statistik, Universität zu Lübeck, Universitätsklinikum 
Schleswig-Holstein, Campus Lübeck, Germany. 
29Institute of Human Genetics, Technische Universität München, Germany. 
30Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, Georgia. 
31Institut für Epidemiologie und Sozialmedizin der Universität Münster, Germany. 
Science Advances                                               Manuscript Template                                                                                           Page 4 of 34 
 
32Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), Institute of Neurogenetics 
and Institute of Integrative and Experimental Genomics, University of Lübeck, Lübeck, 
Germany. 
33School of Public Health, Faculty of Medicine, Imperial College London, London, United 
Kingdom. 
34Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Germany. 
35Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuherberg, 
Germany. 
36Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany. 
37Institute of Human Genetics, University of Bonn, Germany. 
38Department of Biomedicine, Division of Medical Genetics, University of Basel, Switzerland. 
39Interfaculty Institute for Genetics and Functional Genomics, Ernst Moritz Arndt University and 
University Medicine Greifswald, Germany. 
40Institute of Medical Informatics, Biometry and Epidemiology, University Hospital Essen, 
University Duisburg-Essen, Germany. 
41Department I of Internal Medicine, Christian-Albrechts University, Kiel, Germany. 
42Institute of Epidemiology and Biobank popgen, Christian-Albrechts-Universität Kiel, 
Germany. 
43Institute of Genetic Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany. 
44Department of Medicine I, Ludwig-Maximilians-Universität, Munich, Germany. 
45DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, 
Munich, Germany. 
Science Advances                                               Manuscript Template                                                                                           Page 5 of 34 
 
46Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, 
Germany. 
47Department of Neurology, University Medicine Greifswald, Germany. 
48Institute of Medical Informatics, Biometry and Epidemiology, Chair of Genetic Epidemiology, 
Ludwig-Maximilians-Universität, Munich, Germany. 
49Institute for Community Medicine, University Medicine Greifswald, Germany. 
50Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, 
Monserrato, Cagliari, Italy. 
51Dipartimento di Scienze Biomediche, Università degli Studi di Sassari, Italy. 
52Center for Advanced Studies, Research and Development in Sardinia (CRS4), Pula, Italy. 
53Zentrum für Klinische Studien, Universität zu Lübeck, Germany. 
54School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, 
Pietermaritzburg, South Africa. 
55Institute of Translational Medicine, University of Liverpool, United Kingdom. 
†: These authors contributed equally to this work 
*: To whom correspondence should be addressed: hemmer@tum.de and bmm@psych.mpg.de 
  
Science Advances                                               Manuscript Template                                                                                           Page 6 of 34 
 
H2:Abstract 
We conducted a genome-wide association study (GWAS) on multiple sclerosis (MS) 
susceptibility in German cohorts with 4,888 cases and 10,395 controls. In addition to 
associations within the MHC region, fifteen non-MHC loci reached genome-wide significance. 
Four of these loci are novel MS susceptibility loci. They map to the genes L3MBTL3, MAZ, 
ERG, and SHMT1. The lead variant at SHMT1 was replicated in an independent Sardinian 
cohort. Products of the genes L3MBTL3, MAZ, and ERG play important roles in immune cell 
regulation. SHMT1 encodes a serine hydroxymethyltransferase catalyzing the transfer of a 
carbon unit in the folate cycle. This reaction is required for regulation of methylation 
homeostasis, which is important for establishment and maintenance of epigenetic signatures. Our 
GWAS approach in a defined population with limited genetic substructure detected associations 
not found in larger, more heterogeneous cohorts, thus providing new clues regarding MS 
pathogenesis. 
 
H1 MAIN TEXT 
H2:Introduction 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system. Human 
leukocyte antigen (HLA) alleles, located within the major histocompatibility (MHC) region, have 
been identified as major genetic determinants for the disease (1, 2). In addition, more than 100 
non-MHC MS susceptibility variants have been described (3, 4). Many of the genes carrying 
known susceptibility variants are involved in the regulation of either immune cell differentiation 
or signaling (4-8). However, as the heritability of MS is limited (9), environmental contributions 
to disease etiology are also important (10). Environmental influences can alter gene expression 
via epigenetic mechanisms (11). Epigenetic alterations, such as DNA methylation or histone 
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modifications, have been observed in tissue and cells of MS patients (8, 12-14). Nevertheless, the 
impact of epigenetic regulation in MS is not yet understood. 
The known genetic variants outside the MHC region have predominantly been established in 
large international collaborative studies. In order to achieve large sample sizes with the power to 
detect associations, these studies have combined sample sets from diverse ethnic populations (4-
6). So far, the variants affecting MS susceptibility identified in these studies account for only 25 
% of disease heritability under an additive model of heritability (3), warranting for additional 
studies to fully unravel the genetic contribution to disease susceptibility. In contrast to the 
previously investigated large international cohorts, we have strived to examine the genetic 
contribution to MS susceptibility in a more homogenous population, focusing entirely on 
German cases and controls. The genetic substructure among Germans is low (15). We therefore 
expected to have sufficient power to detect novel associations with moderate effect sizes in a 
data set showing little population stratification. Indeed, with a total of 4,888 cases and 10,395 
controls, we had 80 % power to detect genome-wide significant associations with an odds ratio 
(OR) of 1.2 involving common variants with a minor allele frequency (MAF) of 21 %. For rare 
SNPs (MAF 1 %) the power surpassed 80 % for an OR of 1.9. 
H2: Results  
Genome-wide association analyses 
We recruited patients with either MS or clinically isolated syndrome (CIS) from MS centers 
throughout Germany and combined them with controls from several German population-based 
cohorts (table 1). After quality control (QC), this data set DE1 consisted of 3,934 cases and 8,455 
controls (control/case ratio 2.15, table S1). We also compiled a second data set, called DE2, 
based on an independent group of German cases previously used in the IMSGC/WTCCC2 MS 
study (5) (table 1), and additional German controls, mostly from population-based cohorts. This 
data set DE2 contained 954 cases and 1,940 controls after QC (control/case ratio 2.03, table S2). 
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We observed only moderate population substructure within these data sets (figs. S1 and S2), 
confirming previous genetic analyses of the German population (15). 
Both data sets were imputed separately to the 1000 genomes Phase I reference panel using 
SHAPEIT2 and IMPUTE2 (16-18). The resulting data sets contained over eight million high-
quality variants with MAFs of at least 1% each. We conducted genome-wide association 
analyses (GWAS) on both data sets separately, using sex and the first eight multi-dimensional 
scaling (MDS) components of the genetic similarity matrix (GSM) as covariates, to control for 
any remaining population substructure. After assuring that the median genomic inflation of the 
two GWAS was in the expected range (table S3), results were combined using a fixed-effects 
pooled analysis. In this pooled analysis, the genomic inflation 1000,1000 outside the extended 
MHC region was 1.017 (table S3) (19). 
Associations within the MHC region 
The variant showing the strongest association in the pooled analysis of DE1 and DE2, rs3104373 
(OR 2.90, confidence interval (CI) 2.72-3.09, p-value 1.3×10-234), lies within the MHC region 
between the genes HLA-DRB1 and HLA-DQA1. This single nucleotide polymorphism (SNP) is 
in strong linkage disequilibrium (LD) with the HLA allele DRB1*15:01 (r2 = 0.99) and thus 
corresponds to the established major MS risk locus (1, 2). In order to confirm this finding, we 
imputed classical HLA alleles from our genotyping data (20). After QC, we obtained high-quality 
imputed alleles for a total of 3,966 cases and 8,329 controls from DE1 and DE2 (median 
accuracy 96.1 %, median call rate 97.4 %). Using step-wise conditional logistic regression (1, 2, 
5), seven HLA alleles (table 2) reached genome-wide significance (i.e., p-values < 5×10-8). As 
expected, the most significantly associated allele was DRB1*15:01 (OR 2.85 (2.66-3.06), 
p-value 1.0×10-191). All seven alleles have been described as associated with MS in a recent 
detailed analysis of the MHC region (2). 
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Previous analyses of the MHC region have also identified associations between HLA alleles and 
the age at onset of the disease, mainly with DRB1*15:01 (2, 5). We confirmed this finding in a 
subset of patients from our data set DE1. Age at onset was known for 1,519 patients, for 1,196 of 
them imputed HLA alleles were available. As the age at onset was not normally distributed, rank-
based inverse normal transformation was applied. The HLA allele most strongly associated with 
transformed age at onset was DRB1*15:01 (effect size -0.21, p-value 7.6×10-6). When 
conducting a genome-wide analysis of transformed age at onset in all 1,519 patients, no variant 
passed the threshold for genome-wide significance (fig. S3A-B). The most strongly associated 
SNP was rs4959027 (effect size -0.20, p-value 1.5×10-7; fig. S3C-D), which is in LD with 
DRB1*15:01 (r2 = 0.72). After conditioning for DRB1*15:01 in the subset of cases with both age 
at onset and imputed HLA alleles available, the p-value of rs4959027 increased from 1.1×10-6 to 
0.048. We conclude that our findings for the MHC region are very well in line with previous 
studies and concentrated further analyses on associations with case/control status outside this 
region.  
Associations outside the MHC region 
Variants at fifteen loci outside the MHC region showed genome-wide significance (figs. 1, S4, 
S6; tables 3, S4). Ten of these loci have already been established in previous large MS GWAS 
(3, 4, 6). One more locus, DLEU1, was only recently confirmed to be associated with MS in a 
candidate gene study (21). The remaining four signals are thus novel candidates for MS 
susceptibility loci. The lead variants at all fifteen non-MHC loci showed p-values < 5×10-6 in 
DE1 and lower p-values < 5×10-8 in the pooled analysis of DE1 and DE2 and have thus 
replicated in DE2. We could not detect any significant interaction among the 15 top non-MHC 
variants or between them and SNP rs3104373 within the MHC region. 
For validation of our findings, we compared our results to the largest study on MS genetic 
susceptibility published to date (4) (fig. 2). Of the 108 non-MHC variants showing genome-wide 
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significant or suggestive associations with MS in the published study, 104 variants were present 
in our data and could be analyzed. All of them showed the same direction of effect (p-value of 
binomial sign test 5×10-32, CI 0.97-1.00), 84 with nominal (p < 0.05) and ten with genome-wide 
significance (p < 5×10-8). 58 of the variants had lower and 35 higher ORs in our data than in the 
published data set (4). It was expected to observe more signals with lower ORs than previously 
reported due to regression towards the mean. 
Next, we examined the four novel loci as well as DLEU1, not found at genome-wide significance 
in a GWAS before, in more detail. We investigated whether the five lead variants at these loci 
are significantly associated with MS in our German cohort only or whether they replicate in 
Sardinians, a genetically distinct population with low genetic heterogeneity. This independent 
Sardinian cohort consisted of 2,903 cases (69.2 % female, 1.2 % PPMS) and 3,323 controls 
(control/case ratio 1.15) (22-24). Two of the variants (rs2812197 and rs4925166) replicated with 
p-values < 0.01 in the Sardinian data set, two more (rs34286592 and rs2836425) showed the 
same direction of effect but did not reach nominal significance (tables 3, S4; fig. S5). 
SHMT1 as a novel MS susceptibility gene 
The association of rs4925166 constituted the strongest signal among the novel variants. It 
showed an OR of 0.85 (CI 0.81-0.90) and a p-value of 2.7×10-9 in the pooled analysis of German 
data sets (table 3). This variant replicated in the Sardinian cohort with a joint p-value of 7.4×10-12 
(fig. S4). SNP rs4925166 is located on chromosome 17 in an intron of the gene TOP3A, coding 
for the DNA Topoisomerase III Alpha. However, strongly associated SNPs in this genomic 
region spread over several neighboring genes (fig. 3A). We therefore conducted an expression 
quantitative trait locus (eQTL) analysis using a subset of 242 patients from data set DE1 in order 
to functionally link variants to nearby genes. We examined transcripts within a cis window of 
1M base pairs up- and downstream of the lead variant for an association of blood gene 
expression levels with allele configuration (table S5). The variant rs4925166 and proxy SNPs (r2 
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> 0.7) were found to be part of a strong eQTL with the gene SHMT1 in DE1 samples (false 
discovery rate (FDR) 2.99×10-10, table 4, fig. S8). This eQTL was replicated in two independent 
control data sets (Max Planck Institute of Psychiatry data (MPIP) (25) and Grady Trauma Project 
(GTP) (26-28)) as well as in the publicly available GTEx eQTL database (29) (table 4). 
To investigate how rs4925166 influences the expression of SHMT1, we conducted an association 
analysis of the SNP with DNA methylation levels in blood. DNA methylation is an important 
epigenetic mechanism for regulation of gene expression. We tested the association between 
rs4925166 and DNA methylation levels at CpG sites in the two non-MS data sets MPIP and 
GTP. Methylation levels at 157 CpG sites that mapped to SHMT1 were examined for an 
association with genotype. We observed eight significant (FDR < 0.05) methylation QTLs 
(mQTLs) between rs4925166 and CpGs in SHMT1 within the MPIP data set. Three of these 
associations replicated in the GTP data set (table S6).  
We wondered whether the CpG site showing the strongest association with rs4925166 
(cg26763362) could fully explain the observed association between the SNP and SHMT1 
expression (causal direction: rs4925166  cg26763362  SHMT1 expression) using mediation 
analysis (tables 5, S7, S8, figs. 3, S8) (30). We observed partial mediation of the effect of 
rs4925166 on SHMT1 expression by DNA methylation status of CpG site cg26763362. The 
association pattern indicates that an additional factor influences the relationship between the 
SNP, the CpG, and gene expression (see supplementary material). Thus, we conclude that the 
genotype of rs4925166 affects the expression of SHMT1 in a complex fashion, partially 
involving rs4925166-dependent DNA methylation. 
Additional novel candidate loci associated with MS 
Three loci showed genome-wide significance in the pooled analysis of German data sets DE1 
and DE2 but not in Sardinians (table 3). The strongest association, rs4364506, was found on 
chromosome 6 and is located in an intron of the gene coding for the transcriptional regulator 
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L3MBTL3 (Lethal(3)malignant brain tumor-like protein 3, fig. S6G). SNP rs2836425 on 
chromosome 21 constituted the second-strongest signal identified in Germans only. This variant 
maps to an intron of the gene ERG, coding for the transcription factor called V-Ets Avian 
Erythroblastosis Virus E26 Oncogene Homolog (fig. S6P). Thirdly, SNP rs34286592 is located 
in an intron of the gene MAZ on chromosome 16, coding for the transcription factor MYC-
Associated Zink Finger Protein (fig. S6N). It maps to binding sites for transcription factors (fig. 
S7G).  
When conditioning for the lead variants at the four newly identified MS-associated loci, no 
evidence for secondary signals was found. Thus, the lead variants also constitute the most likely 
causal variants. These variants all map to introns of genes. This makes a functional link between 
each variant and the gene it is located in probable. In order to further explore the functional 
connections between SNPs and genes, we conducted an eQTL analysis of the fifteen loci 
showing genome-wide significant associations. We thereby identified four cis-eQTLs with FDR 
< 0.05 in MS cases (table S5). In addition to the eQTL of rs4925166 and SHMT1 already 
described above, three more significant eQTLs involved variants at two previously known MS 
susceptibility loci and three transcripts of the genes MMEL1 and ANKRD55. 
Fine-mapping of DLEU1  
Three variants located on chromosome 13 (rs806321, rs9596270, and rs806349), all intronic 
within the gene for the long non-coding RNA DLEU1 (Deleted in Lymphocytic Leukemia 1), 
have been described previously as associated with MS in three large studies (4-6), yet the 
variants did not show genome-wide significance in any of them. The association of rs806349 has 
recently been confirmed in a candidate-driven follow-up analysis of suggestive MS associations 
(21). However, this variant rs806349 reached a p-value of only 2.7×10-4 in our analysis (table 5). 
Instead, a different SNP, rs2812197, in weak LD with rs806349 (r2 = 0.4), showed genome-wide 
significance in the pooled analysis of DE1 and DE2 and also replicated in Sardinians (tables 3, 5; 
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fig. S6K). The association of previously described rs806349 is completely dependent on the 
more strongly associated rs2812197 (table 5). Thus, it is unlikely that rs806349 is the causal SNP 
at this locus. The same is true for rs806321 (5), which is not independent of rs2812197 either 
(table 5). 
The DLEU1 locus contains evidence for a second signal, rs9591325 (table 5, fig. S6L), in poor 
LD with rs2812197, but in high LD with rs9596270, which was identified by Patsopoulos et al. 
as a suggestive MS-associated variant (6). The two signals were partially independent of each 
other (table 5). Interestingly, rs9591325 is located in a clear functional region with binding sites 
for many transcription factors, which is not the case for the other four variants (fig. S7B-F). 
While rs2812197 shows the overall strongest association at DLEU1, the functional data indicates 
that rs9591325 might be either the actual or a second causal variant. Additional studies with 
larger sample sizes are required to fully answer this question. 
H2: Discussion  
The present study constitutes the largest GWAS on MS conducted in a single population to date. 
By pooled analysis of 3,934 cases in data set DE1 and 954 cases in data set DE2, we identified 
strong associations in the MHC region with a p–value of up to 1.3×10-234. In addition, 15 loci 
outside the MHC region were associated at a genome-wide significant level (fig. 1, table 3). 
Associations in the MHC region were examined using imputed HLA alleles. Step-wise 
conditional logistic regression identified DRB1*15:01 and six more associated HLA alleles (table 
2), in line with results from previous studies (2). All genome-wide significant and suggestive 
non-MHC MS susceptibility variants published by the IMSGC in 2013 (4) and present in our 
data (n = 104) were replicated regarding direction of effects in our samples (p-value 5×10-32, fig. 
2).  
Four of the 15 non-MHC loci have not been found to be associated with MS in previous studies. 
One more locus, DLEU1, did not reach genome-wide significance in previous GWAS but has 
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recently been confirmed as MS-associated in a candidate SNP study (21). The lead variants at 
DLEU1 and at the novel locus SHMT1 replicated in an independent Sardinian cohort containing 
2,903 cases (table 3, fig. S5). Variants at the other three novel loci did not reach nominal 
significance in Sardinians yet two of them showed the same direction of effect. Due to their 
consistency and replication within the German cohorts, these three associations can nevertheless 
be considered as plausible. As the Sardinian population is genetically distinct from Germans, 
future studies are required to replicate these findings in other cohorts.  
Previous genetic analyses of MS susceptibility have indicated immune system related processes 
as relevant for the development of MS (4). Functions of known MS susceptibility genes have 
been mapped to KEGG pathways JAK-STAT signaling, acute myeloid leukemia (AML), and T 
cell receptor signaling (7). Accordingly, MS-associated genes are predominantly expressed in 
immune cells (7, 8). The five genes examined in detail in our study (L3MBTL3, DLEU1, MAZ, 
ERG, and SHMT1) are associated with regulatory mechanisms in immune cells as well.  
The gene L3MBTL3 encodes a Polycomb-group protein that maintains the transcriptionally 
repressive state of genes (31) and is frequently deleted in several forms of acute leukemia, 
including AML (32). Genes associated with AML constitute one of the most significant pathway 
categories linked to MS susceptibility variants (7). The murine ortholog of L3MBTL3, MBT-1, 
has been found to regulate maturation of myeloid progenitor cells (33). The regulatory, long non-
coding RNA DLEU1 is often deleted in cases of B-cell chronic lymphocytic leukemia and 
mantle cell leukemia (34). This locus regulates expression of NF-κB (35), a transcription factor 
implicated in MS pathology (4, 36, 37). MAZ is an inflammation-responsive transcription factor 
(38) upregulated during chronic myeloid leukemia (39). It binds to the promoter of the gene 
MYC, which is associated with MS (5). The transcription factor ERG is important for 
hematopoiesis (40), expression of this oncogene is associated with both AML and acute T-cell 
lymphoblastic leukemia (41). ERG regulates the expression of MS-associated NF-κB (42), as 
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DLEU1 does. Finally, SHMT1 is a serine hydroxymethyltransferase acting in the folate cycle. It 
catalyzes the transfer of a carbon unit subsequently used for synthesis of both nucleotides and 
methionine. SHMT1 is thus an essential component in the metabolism of the substrate 
S-adenosylmethionine (SAM), the major methyl group donor during both protein and DNA 
methylation (43, 44). By this effect on regulation of gene expression, one-carbon metabolism 
plays an important role in oncogenesis. Lack of SHMT1 function is, among other effects, 
associated with acute lymphocytic leukemia (44-46). Thus, each of the five genes is involved in 
regulatory processes of the immune system. 
While a clearer picture has already emerged regarding the cell types and broad pathways relevant 
for the etiology of multiple sclerosis (3, 7), little is still known about the mechanisms by which 
risk genes act. Analysis of the known functions of the five genes examined in this study revealed 
that four of them regulate transcription, especially of immune-related genes. Moreover, indirect 
evidence suggests that they could all be linked either directly or indirectly to epigenetic 
regulatory mechanisms: L3MBTL3 recognizes epigenetic histone lysine methylation (31) and 
ERG interacts with ESET, a histone H3-specific methyltransferase (47). The best known 
regulatory target of the transcription factor MAZ is MYC (48), a regulator of epigenetic 
chromatin state that is associated with MS (5, 49). DLEU1 is strictly regulated by DNA 
methylation at its promoter region (35). Finally, SHMT1 is essential for maintaining methylation 
homeostasis in the cell by catalyzing an important reaction in the generation of the methyl donor 
substrate SAM. Accordingly, establishment of SHMT1 as a MS risk factor puts epigenetic 
regulation by methylation further in the focus of MS susceptibility. 
In recent years, several studies have addressed the role of DNA methylation in the etiology and 
progression of MS. Methylation differences between MS cases and healthy controls have been 
analyzed in small, cross-sectional studies. Despite negative results in CD4+ cells (12, 50), Bos 
and colleagues recently observed significant differences in overall DNA methylation levels in 
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CD8+ T cells (12). Another study demonstrated differentially methylated and expressed genes in 
brain tissue of MS patients compared to controls (14). Furthermore, differential methylation of 
the major risk locus HLA-DRB1 was observed in MS patients (51). Several groups have found 
either hyper- or hypomethylation of specific genes to be associated with inflammation or 
demyelination in MS patients (11).  
In summary, these studies argue in favor of DNA methylation being relevant for the 
development of MS. By finding novel risk genes with potential roles in epigenetic regulation, our 
study adds further indication that epigenetic mechanisms might be important for MS 
susceptibility. Especially a disturbed homeostasis of methyl donors, caused by an altered 
expression of SHMT1, is likely to have an impact on the disease. As epigenetic mechanisms 
constitute a major route for environmental risk factors to influence expression of disease-
associated genes (11), regulation of DNA and protein methylation is an interface where genetic 
and environmental risk factors for MS might intersect. Detailed analyses of DNA methylation 
patterns and their interaction with MS susceptibility genes in larger cohorts and among different 
cell populations and tissues are now required to better understand the role of epigenetic 
mechanisms in MS. 
 
H2: Materials and Methods 
Study samples 
Two cohorts of cases, referred to as DE1 and DE2, have been analyzed. Both data sets included 
patients with CIS, bout onset MS, and primary progressive MS. For cohort DE1, 4,503 cases 
have been recruited across multiple sites in Germany (for details see the supplementary 
material). For cohort DE2, 1,002 cases have been recruited across multiple sites in Germany (see 
supplementary material). The latter cohort has been used in a previous publication (5). Controls 
for these cohorts were obtained from several population-based cohorts across Germany, to match 
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the different geographical regions where cases were recruited: KORA from the South-Eastern 
German region of Augsburg (52, 53), HNR from central Western Germany (54), SHIP from the 
North-Eastern region West Pomerania (55), DOGS from Dortmund in central Western Germany 
(56), FoCus (57) and popgen (58) from Kiel in Northern Germany. In addition, controls from 
two studies on depression conducted in South-Eastern Germany were included (59, 60). For a 
more detailed description of control cohorts see the supplementary material. All responsible 
ethics committees have provided positive votes for the individual studies. All study participants 
gave written informed consent. In case of minors, parental informed consent was obtained.  
Genotyping and quality control 
Samples of cohort DE1 have been genotyped using the Illumina HumanOmniExpress-24-V1-0 
or -V1-1 BeadChips. Samples of cohort DE2 have been genotyped using the Illumina Human 
660-Quad platform. For both cohorts, identical, stringent QC was conducted on samples and 
variants. QC steps on samples included removal of individuals with genotyping rate < 2 %, 
cryptic relatives (relatedness  1/16), and genetic population outliers. QC steps on variants 
included removal of variants with call rate < 2 % and MAF < 1%. For a full description of QC, 
see the supplementary material. Each set of cohorts was combined with controls genotyped on 
similar arrays, producing case/control data sets DE1 and DE2. QC was repeated on the merged 
data sets, leading to final figures of 3,934 cases and 8,455 controls for DE1 (table S1), as well as 
954 cases and 1,940 controls for DE2 (table S2).  
Imputation 
Pre-phasing (haplotype estimation) of genotype data was conducted using SHAPEIT2, followed 
by imputation using IMPUTE2 in 5 Mbp chunks (16-18). The 1000 genomes phase I June 2014 
release was used as a reference panel. Imputed variants were filtered for MAF  1 %, INFO 
metric  0.8 and HWE p-value  10-6. For additional details see the supplementary material. 
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HLA alleles were imputed from genotyping data separately for DE1 and DE2 using HIBAG 
v1.6.0 (20). Alleles with a posterior probability >0.5 were converted to hard calls. Results were 
validated using HLA typing of 442 patients from DE1 (see supplementary material).  
Statistical analyses of genotype data 
GWAS were conducted on data sets DE1 and DE2 using PLINK2 v1.90b3s (61). Sex and the 
first eight MDS components were used as covariates in logistic regression. Data sets were 
combined using a fixed-effects model in METASOFT (62). For maximum precision, logistic 
regression and meta analysis of lead SNPs were repeated in R v3.2.3 using package meta v4.3.2. 
All follow-up analyses (e.g., conditional and interaction analyses) were conducted in R. Locus-
specific Manhattan plots were generated using LocusZoom with EUR samples of the 1000 
genomes March 2012 reference panel on the hg19 build (63). For analysis of HLA alleles, step-
wise logistic regression was conducted in R as described previously (1, 2, 5). 
Gene expression and methylation data 
For a subset of 242, mostly treatment-naïve patients from data set DE1 (73 male, 169 female) 
whole blood RNA was collected using Tempus Blood RNA Tubes (Applied Biosystems, Foster 
City, CA). RNA was hybridized to Illumina HT-12 v4 expression BeadChips (Illumina, San 
Diego, CA) and further processed as described in the supplementary material. In summary, QC 
was conducted in R 3.2.1 using the packages beadarray and lumi (64, 65). Probes were 
transformed and normalized through variance stabilization and normalization (VSN) (66). Probes 
which showed a detection p-value < 0.05 in more than 10 % of the samples, which could not be 
mapped to a known transcript, or which were identified as cross-hybridizing by the Re-Annotator 
pipeline (67) were removed. This left 20,302 transcripts from 242 samples. Technical batch 
effects were identified by inspecting the association of the first two principal components of 
expression levels with amplification round, amplification plate, amplification plate column and 
row, as well as with expression chip. The data were then adjusted using ComBat (68). 
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Gene expression and methylation data of the two control cohorts MPIP (Max Planck Institute of 
Psychiatry) and GTP (Grady Trauma Project) have been published and described previously and 
are summarized in the supplementary material (25-28). 
Statistical analysis of gene expression and methylation data 
For each of the 15 genome-wide significant loci, all 429 transcripts beginning or ending within 1 
Mbp up- or downstream of a lead variant were determined. Associations between genotype and 
expression levels were examined in data set DE1 by linear regression, using sex, age, and 3 MDS 
components as covariates. To account for multiple testing, p-values were first corrected for the 
number of transcripts per cis window, followed by calculation of the FDR for the total number of 
variants tested. Replication of eQTLs with an FDR < 0.05 in data set DE1 was conducted in 
control cohorts MPIP and GTP. For MPIP, the covariates sex, age, BMI, disease status, and 3 
MDS components were used in linear regression. For GTP, covariates were sex, age, and 4 MDS 
components. eQTLs were also looked up in the GTEx database (29). Here, only associations in 
whole blood were considered. 
For analysis of the association of rs4925166 with DNA methylation at SHMT1, 210 CpG probes 
were identified in data set MPIP that mapped to SHMT1. After removing the quartile of probes 
showing the lowest variation in methylation status, 157 CpGs remained. Association of DNA 
methylation with imputed genotype was assessed by linear regression, using sex, age, BMI, 
disease status, 3 MDS components, and estimated cell counts as covariates. The eight CpG 
probes showing an FDR < 0.05 were replicated in data set GTP, using sex, age, 4 MDS 
components, and estimated cell counts as covariates. Mediation analysis was conducted as 
outlined in the supplementary material, including nonparametric bootstrap for estimation of 
confidence intervals and p-values (30). 
Replication of the results in a Sardinian cohort 
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The replication case group consists of the 2,903 unrelated Sardinian MS patients that were 
diagnosed and selected using the McDonald criteria (22-24). Only 35 of these patients were 
diagnosed with PPMS (1.2 %). 2,010 (69.2 %) cases were female, 893 (30.8 %) male, the 
average age at onset was 32 years. The matching control group of healthy individuals is 
composed of 2,880 unrelated adult volunteer blood donors from the same locations where the 
cases have been collected, as well as 443 Affected Family BAsed pseudo-Controls (AFBAC) 
derived from 242 MS and 201 type 1 diabetes family trios (23). AFBAC allele and haplotype 
frequencies were constructed using the two alleles in each trio that are not transmitted from the 
parents to the affected child. These familial pseudo-controls are matched to the cases for ethnic 
origin and are thus robust to population stratification. 
All individuals were genotyped using the Illumina ImmunoChip array. In addition, 2,040 (962 
cases and 1,078 controls) were genotyped with the Illumina HumanOmniExpress array and 3,917 
(2,111 cases and 1,806 controls) with the Affymetrix 6.0 array. 174 individuals (170 case and 4 
controls) were genotyped using both HumanOmniExpress and Affymetrix 6.0 (22). After quality 
control, we used 883,557 SNPs as baseline for imputation (17) of 20.1 million untyped SNPs 
using a Sardinian-specific reference panel including 3,514 Sardinian individuals sequenced to an 
average coverage of 4.16-fold (69). 
 
H2: Supplementary Materials 
Results 
Fig. S3: Age at onset. 
Fig. S4: Forest plots of all top genome-wide significant variants. 
Fig. S5: Forest plots of novel variants replicated in a Sardinian cohort. 
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Fig. S7: Transcription factor binding sites. 
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H3: Data and materials availability:  
All data needed to evaluate the conclusions in the paper are present in the paper and the 
supplementary materials or are available from authors upon request. 
 
H2: Figures and Tables 
Fig. 1. Genome-wide representation of MS associations in the pooled analysis of German 
data sets 
Manhattan plot showing strength of evidence for association (p-value). Each variant is shown as 
a dot, with alternating shades of blue according to chromosome. Green dots represent established 
MS-associated variants and their proxies, as listed by Sawcer et al. (3) (except for rs2812197, 
which was not covered by that review). Top variants at the 15 non-MHC loci associated at the 
genome-wide significance threshold in our study are shown as diamonds. Novel variants 
showing genome-wide significance are plotted as red diamonds, their names are shown in bold 
font. Variants in high linkage disequilibrium (r2  0.7) with these novel variants are shown as red 
dots. Variants replicating in the Sardinian cohort are shown in red font. MA = minor allele, OR = 
odds ratio (relative to the MA). Gene names for known loci are indicated as listed by Sawcer et 
al. (3). The plot is truncated at -log10(p) = 16 for better visibility, all truncated variants map to 
the MHC region. The lowest p-value (rs3104373, *) was 1.3×10-234.  
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Fig. 2. Comparison of results from the pooled analysis of Germans to associations found in 
an IMSGC study.  
104 of the 108 variants showing genome-wide significant or suggestive associations with MS in 
the study published by the IMSGC in 2013 (4) were present in the pooled results of DE1 and 
DE2. All 104 variants showed the same direction of effect (binomial test p-value 5×10-32). 58 
variants had lower and 35 higher ORs compared to the published data set. P-value-based 
categories labeled with different dots represent exclusive bins that add up to 104. CI = 95 % 
confidence interval, OR = odds ratio. 
 
Fig. 3. Fine-mapping analysis results of locus rs4925166. 
(A): Regional plot for the rs4925166/SHMT1 locus. Color of dots indicates LD with the lead 
variant (rs4925166, shown in pink). Grey dots represent signals with missing r2 values.  
(B): Mediation analysis results in MPIP/GTP controls. Mediation effect: rs4925166  CpG 
cg26763362  SHMT1 expression. Direct effect: rs4925166  SHMT1 expression. Data has 
been calculated using the R package mediation (30), except for total effect (*), which was 
calculated by linear regression. Results were obtained using 1,000,000 simulations. Effects and 
p-values shown here differ from table 5, as a lower number of samples contained both expression 
and methylation data than expression data alone. (C): Relationship between cg26763362 
methylation, SHMT1 expression, and rs4925166 genotype in MPIP controls. 
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 Cohort DE1 Cohort DE2 
Number of cases 3934 954 
Age [mean (range)] 39 (13-79) 40 (17-82) 
Female [n (%)] 2723 (69.2) 695 (72.9) 
Male [n (%)] 1211 (30.8) 259 (27.1) 
PPMS [n (%)] 105 (2.7) 63 (6.6) 
Table 1: Clinical characteristics of German MS cases.  
PPMS = Primary progressive MS (as opposed to bout onset MS). 
 
HLA allele AF OR (95 % CI) p-value 
HLA alleles in 
LD (r2 > 0.9) 
DRB1*15:01 14.8 2.85 (2.66-3.06) 1.03×10-191 DQB1*06:02 
A*02:01 28.6 0.68 (0.64-0.73) 3.68×10-29 
 
B*38:01 2.0 0.36 (0.27-0.49) 2.09×10-11 
 
DRB1*13:03 1.5 1.96 (1.60-2.40) 6.42×10-11 
 
DPB1*03:01 10.3 1.33 (1.22-1.46) 4.35×10-10 
 
DRB1*03:01 12.2 1.29 (1.18-1.40) 1.85×10-08 
DQA1*05:01, 
DQB1*02:01 
DRB1*08:01 3.0 1.63 (1.39-1.91) 2.36×10-09 
DQA1*04:01, 
DQB1*04:02 
Table 2: Genome-wide significant HLA alleles. 
Alleles are in order of step-wise logistic regression. For each row, alleles from the rows above 
have been used as covariates in the model. AF (allele frequency of controls in %) is calculated 
from a joint set of DE1 and DE2. ORs and p-values are from a fixed-effects pooled analysis of 
DE1 and DE2. 
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Variant C MA Gene 
MAF 
DE 
OR (CI) 
DE1+DE2 
p-value 
DE1+DE2 
p-value 
Sardinia 
OR (CI) 
DE+Sard. 
p-value 
DE+Sard. 
rs10797431 1 T MMEL1 34.1 
0.84 
(0.80-0.89) 
1.81×10-10 
   
rs6689470 1 A EVI5 14.2 
1.24 
(1.16-1.33) 
3.93×10-10 
   
rs2300747 1 G CD58 12.4 
0.75 
(0.69-0.81) 
1.74×10-12 
   
rs7535818 1 G RGS1 19.2 
0.76 
(0.71-0.82) 
1.51×10-15 
   
rs2681424 3 C CD86 49.7 
0.86 
(0.82-0.90) 
9.51×10-10 
   
rs6859219 5 A ANKRD55 22.2 
0.84 
(0.79-0.89) 
8.06×10-09 
   
rs3104373 6 T HLA-DRB1 13.6 
2.90 
(2.72-3.09) 
1.34×10-234 
   
rs4364506 6 A L3MBTL3 26.4 
0.84 
(0.80-0.89) 
4.06×10-09 0.83 
0.89 
(0.85-0.93) 
1.99×10-06 
rs2182410 10 T IL2RA 38.1 
0.84 
(0.79-0.88) 
1.15×10-11 
   
rs1891621 10 G Intergenic 46.7 
0.87 
(0.83-0.91) 
2.94×10-08 
   
rs1800693 12 C TNFRSF1A 42.1 
1.17 
(1.11-1.23) 
1.06×10-09 
   
rs2812197 13 T DLEU1 38.4 
0.86 
(0.82-0.91) 
9.95×10-09 6.86×10-03 
0.87 
(0.83-0.91) 
2.83×10-10 
rs6498168 16 T CLEC16A 35.5 
1.23 
(1.17-1.29) 
1.98×10-15 
   
rs34286592 16 T MAZ 14.2 
1.21 
(1.13-1.30) 
4.58×10-08 0.44 
1.16 
(1.09-1.23) 
4.79×10-07 
rs4925166 17 T SHMT1 34.5 
0.85 
(0.81-0.90) 
2.69×10-09 5.63×10-04 
0.86 
(0.82-0.90) 
7.40×10-12 
rs2836425 21 T ERG 12.7 
1.22 
(1.14-1.31) 
2.84×10-08 0.35 
1.18 
(1.11-1.25) 
1.54×10-07 
Table 3: Genome-wide significant loci outside the MHC region and the top variant within 
the MHC region. 
Bold font in the left half of the table indicates novel loci, bold font in the right half variants that 
replicated in Sardinians. All p-values shown in the table are two-sided. Gene names of known 
loci are as listed by Sawcer et al. (3). C = Chromosome, MA = Minor allele. For additional 
details see table S4. 
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Expression 
Data set Transcript Effect p-value FDR 
DE1 SHMT1 0.36 4.42×10-13 2.99×10-10 
MPIP SHMT1 0.19 4.26×10-12 1.28×10-11 
GTP SHMT1 0.11 3.12×10-04 1.25×10-03 
GTEx SHMT1 0.56 09.2×10-28 NA 
Methylation 
Data set CpG Effect p-value FDR 
MPIP cg26763362 -0.03 3.21×10-20 5.04×10-18 
GTP cg26763362 -0.03 1.98×10-14 1.58×10-13 
Table 4: eQTL and mQTL analysis for rs4925166.  
Direction of effect is relative to the minor allele T. Note that the effect sizes cannot be directly 
compared as normalization methods and covariates partly differ between studies. Additional 
eQTLs and mQTLs are described in the supplementary material. As only the single eQTL 
rs4925166/SHMT1 was examined in GTEx data, no FDR is indicated here.  
 
Variant MAF OR (CI) p-value 
p-value  
(rs281297) 
p-value  
(rs9591325) 
r2 Ref. 
rs2812197 38.4 
0.86 
(0.82-0.91) 
9.95×10-9 
 
4.79×10-5 1.00  
rs806321 48.5 
0.89 
(0.85-0.94) 
6.36×10-6 0.81 2.02×10-3 0.66 (5) 
rs806349 46.0 
1.10 
(1.04-1.15) 
2.73×10-4 0.99 0.019 0.41 (4, 21) 
rs9591325 8.1 
0.78 
(0.70-0.85) 
2.26×10-7 9.13×10-4 
 
0.14  
rs9596270 8.1 
0.78 
(0.71-0.86) 
4.45×10-7 1.49×10-3 0.27 
0.14 
(0.99†) 
(6) 
Table 5: Fine-mapping of the DLEU1 locus. 
MAF (controls in %) and r2 (with rs2812197) are calculated from a joint set of DE1 and DE2, 
ORs and p-values from the pooled analysis of DE1 and DE2. Second and third p-value columns 
are from conditional analysis. †: r2 with rs9591325. 
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